title: Time to recover from atrial hormonal, mechanical, and electrical dysfunction after successful electrical cardioversion of persistent atrial fibrillation.
abstract: Although transient atrial dysfunction has been reported after electrical cardioversion of atrial fibrillation (AF), the difference in the time to recover from the atrial hormonal, mechanical, and electrical dysfunction has not been described. Thus, we evaluated the time course of recovery from atrial hormonal, mechanical, and electrical dysfunction after cardioversion in patients with nonvalvular AF. We attempted electrical cardioversion in 87 consecutive patients with nonvalvular AF that had persisted for > or =6 months, and in 24 patients (28%) with maintained sinus rhythm for > or =6 months. To evaluate atrial hormonal, mechanical, and electrical dysfunction in these 24 patients, we measured plasma concentration of atrial natriuretic peptide, the atrial peak velocity in transmitral flow, and the ratio of peak systolic-to-diastolic pulmonary venous flow (S/D ratio) using echocardiography, and the duration and the root mean voltage for the terminal 20 ms (LP20) of the filtered P wave using P-wave signal-averaged electrocardiography. Atrial natriuretic peptide rapidly returned to baseline within 1 day after cardioversion, and maintained these levels for 6 months. Atrial peak velocity in transmitral flow and S/D ratio were significantly increased at 2 weeks, and continued to increase until 1 month, and then reached a plateau. The duration and LP20 began to recover only 6 months after cardioversion. One to 3 years after conversion, the duration and LP20 had nearly reached a plateau, but the latter value remained below normal. In patients with nonvalvular AF of prolonged duration, recovery from atrial electrical dysfunction after sinus conversion took much longer than that from either atrial hormonal or mechanical dysfunction.
authors.affiliation: Division of Cardiology, Osaka Rosai Hospital, Sakai, Japan. mnishino@orh.go.jp
authors.forename: M
authors.initials: M
authors.lastname: Nishino
authors.forename: S
authors.initials: S
authors.lastname: Hoshida
authors.forename: J
authors.initials: J
authors.lastname: Tanouchi
authors.forename: T
authors.initials: T
authors.lastname: Ito
authors.forename: J
authors.initials: J
authors.lastname: Kato
authors.forename: K
authors.initials: K
authors.lastname: Iwai
authors.forename: H
authors.initials: H
authors.lastname: Tanahashi
authors.forename: M
authors.initials: M
authors.lastname: Hori
authors.forename: Y
authors.initials: Y
authors.lastname: Yamada
authors.forename: T
authors.initials: T
authors.lastname: Kamada
mesh_terms: D000368:Aged; D001281:Atrial Fibrillation / Q000097:blood / Q000503:physiopathology* / Q000628:therapy; D009320:Atrial Natriuretic Factor / Q000097:blood; D001783:Blood Flow Velocity; D002908:Chronic Disease; D004554:Electric Countershock; D004562:Electrocardiography; D005260:Female; D005500:Follow-Up Studies; D006325:Heart Atria / Q000503:physiopathology; D006801:Humans; D008297:Male; D008875:Middle Aged; D008943:Mitral Valve / Q000503:physiopathology; D013997:Time Factors
chemical_list: D009320:Atrial Natriuretic Factor